PDCD1LG2 and neoplasm: The higher expression of PD-L2 or TNFRSF18 was significantly associated with good survival outcome in LIHC or BRCA/HNSC cancer patients, respectively, after adjusting for the abundances of tumor infiltrating immune cells (Figs 4 and S7).